Multaq (Dronedarone) API Manufacturers & Suppliers

Dronedarone (CAS Number 141626-36-0) is a benzofuran derivative classified as a Class III antiarrhythmic agent. It is indicated for the management of atrial fibrillation (AF) in patients with a history of paroxysmal or persistent AF who are in sinus rhythm, aiming to reduce the risk of hospitalization related to AF. Atrial fibrillation is characterized by irregular, often rapid heart rate caused by abnormal electrical impulses in the atria, which increases the risk of stroke due to thrombus formation.

Dronedarone modulates cardiac excitability by blocking multiple ion channels and adrenergic receptors consistent with all four Vaughan Williams classes. It inhibits sodium (INa), potassium (IKr, IKs, IK1), and calcium (ICa,L) channels while also non-competitively antagonizing alpha- and beta-adrenergic receptors. These actions result in the prolongation of cardiac action potential duration and refractory periods, reduction of heart rate, and deceleration of conduction velocity, which together contribute to maintenance of normal sinus rhythm and rate control in atrial fibrillation.

Pharmacodynamically, dronedarone moderately prolongs the QTc interval by approximately 10 milliseconds on average and exerts vasodilatory effects on coronary arteries through nitric oxide pathway activation. It reduces arterial blood pressure and myocardial oxygen consumption without significantly altering left ventricular ejection fraction. Dronedarone exhibits antiadrenergic properties by attenuating alpha-1 and beta-adrenergic receptor-mediated cardiovascular responses.

The drug is structurally related to amiodarone but lacks iodine substituents, mitigating thyroid-related adverse effects commonly associated with amiodarone. Furthermore, the presence of a methyl sulfonyl group increases lipophilicity and leads to a shorter elimination half-life and lower tissue accumulation, potentially reducing the incidence of organ toxicities such as pulmonary fibrosis and thyroid dysfunction commonly linked to amiodarone.

Key safety considerations include the risk of hepatocellular injury, interstitial lung disease, and worsening heart failure in patients with severe left ventricular systolic dysfunction. Dronedarone is contraindicated in patients with unstable or severe heart failure due to increased mortality risk. It may cause fetal harm based on animal studies at exposures comparable to human therapeutic doses.

Dronedarone undergoes hepatic metabolism primarily via cytochrome P450 enzymes CYP3A4 and CYP2D6 and acts as both substrate and moderate inhibitor of these isoenzymes, which necessitates careful attention to potential drug-drug interactions. Its moderate QT prolongation classifies it among agents with a risk for proarrhythmia, warranting cardiac monitoring during therapy.

Dronedarone is marketed under the brand name Multaq® and has regulatory approval from agencies including the US FDA and Health Canada.

For pharmaceutical sourcing and quality assurance of dronedarone API, suppliers should ensure compliance with pharmacopeial standards and regulatory requirements. Due to its complex multi-target pharmacology, tight control of purity, polymorphic form, and residual solvents is critical for consistent clinical performance and safety. Given its susceptibility to metabolism by CYP450 enzymes, attention to stability and packaging to prevent degradation is recommended. Additionally, sourcing APIs from manufacturers with validated processes and robust impurity profiling is essential to meet regulatory submissions and therapeutic consistency.